ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2024
PCV13, PCV15 or PCV20: Which vaccine is best for children in terms of immunogenicity?
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- The relative immunogenicity of 20-valent and 15-valent pneumococcal conjugate vaccines: A systematic review and network meta-analysis.Human vaccines & immunotherapeutics · 2026Pooled it
- Inequalities in childhood pneumococcal conjugate vaccine uptake in England before and after the change from a 2 + 1 to 1 + 1 schedule: a longitudinal study.The Lancet regional health. Europe · 2026Article
- Invasive Pneumococcal Disease Epidemiology and Conjugate Vaccines in Canada, 2000-2019.JAMA network open · 2026Article
- Nasopharyngeal pneumococcal carriage and serotype landscape in children, adolescents and young adults in Türkiye.European journal of pediatrics · 2026Article
- Review
- Article
- Indirect Comparison of PCV20 Immunogenicity with PCV10 in Pediatric 3 + 1 and 2 + 1 Schedules.Infectious diseases and therapy · 2025Article
- A new approach to define the optimal immunization strategy against pneumococcal disease: the example of Canada.Epidemiology and infection · 2025Article
- Invasive Pneumococcal Disease and Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in Singapore Children Over 24 Years.Open forum infectious diseases · 2025Article
- Immunogenicity and Safety of the Higher-Valent Pneumococcal Conjugate Vaccine vs the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Open forum infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The new 15- and 20-valent pneumococcal conjugate vaccines (PCV15 and PCV20) have been marketed on the basis of immunogenicity criteria, one of them being a non-inferior response as compared with the 13-valent vaccine (PCV13). In the past, PCV13 was also authorized on the basis of the same criteria, using the 7-valent vaccine (PCV7) as a reference. Methods: Our aim was to compare the immunogenicity of these three vaccines in toddlers. Functional opsonophagocytic activity (OPA) titre ratios measured in the same and different randomized trials were computed to assess the respective immunogenicity of these four products. Results: Results suggest that both PCV15 and PCV20 are less immunogenic than PCV13 for most common serotypes and that the two new vaccines induce a broadly similar response. The PCV7 vaccine was already slightly more immunogenic than PCV13 meaning that PCV15 and PCV20 compare poorly with PCV7. Results also point towards a reduced immunogenicity of the 2+1 dose schedule compared to the 3+1 dose schedule for PCV13, PCV15 and PCV20. Conclusion: Post-marketing studies will have to be conducted to assess the effectiveness of PCV15 and PCV20 and their real-life benefit over PCV13.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.